Earnings Release • Nov 7, 2024
Earnings Release
Open in ViewerOpens in native device viewer

Ian Gallienne, CEO of GBL, remarked, "Building on our nine-month results, GBL's teams remain focused on value creation and capital allocation. Over the medium term, our objective is to generate a double-digit total shareholder return annually. We intend to deliver this magnitude of returns through both NAV per share growth and increasing distributions2 to shareholders, while maintaining conservative leverage. As such, we are announcing steady growth in the dividend per share off a significantly increased base of €5.003 . With our solid balance sheet, GBL is well positioned to seize future attractive investment opportunities."
2 Dividends per share
6 Private assets for + €195m (see page 11) and GBL Capital for + €83m (see page 18)

1 Information on GBL's mid-term outlook (2024-2027) can be found in the Strategic Update presentation in the "Investors" section of www.gbl.com
3 Dividend per share of €5.00 payable in FY 2025 for FY 2024 as announced July 31, 2024; as is customary, subject to approval at GBL's General Shareholders' Meeting
4 In accordance with IFRS 9, capital gains (losses) do not impact GBL's consolidated net result
5 Includes capital gains on disposals of (i) €630m in 9M 2024 and (ii) €422m, the latter from forward sales maturing in October 2024
As of September 30, 2024, listed assets accounted for 63% of the portfolio, while private assets and GBL Capital represented 19% and 17%, respectively. The investment to establish Sienna Investment Managers, the core activity of which is third-party asset management (with more than €40bn in AuM at end September 2024), represents €125m, or less than 1% of GBL's NAV.

As part of GBL's strategic shift toward private assets and given the share price rebound of adidas over approximately the past two years, GBL has seized opportunities to crystallize value on its investment. Over the 9M 2024, GBL divested a €999m stake, thereby reducing its holding from 7.6% to 5.1%. These disposals generated a capital gain1 of €630m.
Similarly, GBL executed €653m of forward sales maturing on October 24, 2024, bringing its adidas stake to 3.5% of the capital and generating a capital gain1 of €422m. GBL remains a meaningful shareholder in adidas and reiterates its support to the company, its management and its strategy.
| Consolidated private assets, performance 9M 2024 vs. 9M 2023 | ||||
|---|---|---|---|---|
| Affidea | Sanoptis3 | Canyon | ||
| Sales, €m | 757 | 518 | 655 | |
| Growth, % | 20% | 24% | 6% | |
| Organic growth, % | 13%4 | 11% | 6% | |
| EBITDA growth, % | 27% | 18% | - 19%5 |
Consolidated private assets posted solid double-digit top-line growth, up + 15% on a combined basis.
Source: non-audited company reporting
The healthcare participations reported double-digit organic sales growth, which was significantly complemented by M&A as these companies pursue sector consolidation. Canyon also posted strong sales growth, at + 6%, and once again outpaced the sector. However, profitability5 , and therefore valuation, were impacted. Nevertheless, the consolidated private assets generated an increase in fair value of + €186m6 . The totality of GBL's private assets (including non-consolidated assets or assets accounted for using the equity method) recorded an increase of + €195m7 .
2 Includes capital gains on disposals of (i) €630m in 9M 2024 and (ii) €422m, the latter generated on forward sales maturing in October 2024
7 Affidea, Sanoptis and Canyon (+ €186m in total), Voodoo (+ €10m) and Parques Reunidos (+ €0m)

1 In accordance with IFRS 9, capital gains (losses) do not impact GBL's consolidated net result
3 Includes estimated annualization of closed clinic M&A and clinic M&A projects with signed SPAs at the end of the period, except for organic growth
4 Like-for-like growth, excluding impact of acquisitions done in the latest period and Covid-19 testing
5 EBITDA decline mainly impacted by the reversal of one-off EBITDA adjustments accounted for in 2023 (adjustments for one-off supply chain issues incurred in Q3 2023). Excluding these adjustments, growth would be + 5%
6 Affidea (+ €192m), Sanoptis (+ €54m) and Canyon (- €60m)
GBL Capital created + €83m of value across the business, underscoring a solid performance under a new leadership and strategy.
Sienna Investment Managers generated dynamic commercial synergies, recording net inflows of €1.8bn in Q3 2024, and thereby increasing assets under management to over €40bn.
NAV per share of €117.99 represents an increase of + 3.8% compared to the NAV per share at end 20231 .
As communicated in GBL's HY 2024 results publication, the group will propose for the FY 2024 a gross dividend per share of €5.002 to be paid in FY 2025. This represents an + 82% increase compared to the previous year and a yield of 7.1%3 . This amount is supported by the strength of GBL's balance sheet and liquidity profile, both of which were reinforced following the value crystallization on disposals within the listed asset portfolio.
Given the discount of the share price to NAV (an average of 39.9% in 9M 2024), the group continued to take advantage of attractive market opportunities to buy back shares. Over the period, GBL acquired, directly and through its subsidiaries, 2.8m GBL shares, corresponding to 2.0% of the shares representing the capital as of September 30, 2024, for a total consideration of €190m. These buybacks were realized as part of the group's seventh share buyback envelope (the allocated amount of which is €500m).
GBL's liquidity profile was €4.3bn as of September 30, 2024. The group's strong liquidity, low leverage and balanced debt maturity profile position GBL to seize attractive investment opportunities going forward.
In parallel with this 9M 2024 results publication, GBL is providing a mid-term Strategic Update. As part of this communication, GBL is announcing its objective to generate double-digit TSR per annum over 2024-2027. This performance will result from: (i) NAV per share growth and (ii) increasing distributions to shareholders through steady growth in the €5.002 dividend per share, while pursuing opportunistic share buybacks and maintaining conservative leverage. Additional information can be found in the "Investors" section of GBL's website.
3 Based on GBL's share price of €69.95 as at September 30, 2024

1 €113.64 based on 146,700,000 shares as of December 31, 2023
2 Payable in FY 2025 for FY 2024; as is customary, subject to approval at GBL's General Shareholders' Meeting
As of September 30, 2024, GBL's net asset value amounts to €16.3bn (€117.99 per share), compared to €16.7bn (€113.64 per share) at year-end 2023. Relative to the share price of €69.95, the discount as of end September 2024 stood at 40.7%.
| September 30, 2024 | December 31, 2023 | ||||||
|---|---|---|---|---|---|---|---|
| % in capital |
Stock price (€)1 |
(€m) | Variation | % in capital |
Stock price (€)1 |
(€m) | |
| Listed assets | 10,557 | - 7% | 11,360 | ||||
| SGS | 19.13 | 99.95 | 3,624 | + 28% | 19.31 | 78.34 | 2,835 |
| Pernod Ricard | 6.80 | 135.60 | 2,337 | - 15% | 6.73 | 159.75 | 2,749 |
| adidas | 5.09 | 237.90 | 2,178 | - 14% | 7.62 | 184.16 | 2,526 |
| Imerys | 54.72 | 29.78 | 1,384 | + 5% | 54.64 | 28.48 | 1,322 |
| Umicore | 15.92 | 11.66 | 457 | - 53% | 15.92 | 24.90 | 977 |
| Concentrix | 13.51 | 45.78 | 4092 | - 49% | 13.17 | 88.88 | 8072 |
| Ontex | 19.98 | 8.94 | 147 | + 18% | 19.98 | 7.61 | 125 |
| TotalEnergies | 0.01 | 58.50 | 16 | - 5% | 0.01 | 61.60 | 16 |
| GEA | 0.06 | 43.96 | 5 | + 17% | 0.06 | 37.69 | 4 |
| Private assets | 3,263 | + 6% | 3,067 | ||||
| Affidea | 99.04 | 1,386 | + 16% | 99.15 | 1,195 | ||
| Sanoptis | 83.17 | 883 | + 6% | 83.36 | 829 | ||
| Canyon | 48.783 | 402 | - 13% | 48.653 | 460 | ||
| Voodoo | 15.07 | 297 | + 3% | 15.90 | 287 | ||
| Parques Reunidos | 23.00 | 296 | + 0% | 23.00 | 296 | ||
| GBL Capital | 2,845 | - 4% | 2,951 | ||||
| Sienna Investment Managers4 | 125 | + 14% | 110 | ||||
| Portfolio | 16,791 | - 4% | 17,488 | ||||
| Treasury shares | 795 | - 34% | 1,206 | ||||
| Gross debt | (3,070) | - 14% | (3,578) | ||||
| Concentrix note | 4 | - 99%5 | 476 | ||||
| Gross cash | 1,810 | + 68% | 1,080 | ||||
| Net asset value | 16,330 | - 2% | 16,671 |
| Net asset value (€ p.s.)6 | 117.99 | + 4% | 113.64 |
|---|---|---|---|
| Stock price (€ p.s.) | 69.95 | - 2% | 71.22 |
| Discount | 40.7% | +339 bps | 37.3% |
6 Based on 138,400,000 shares as of September 30, 2024 and 146,700,000 shares as of December 31, 2023

1 Share price converted in € based on the ECB fixing of (i) 0.9439 CHF/€ as of September 30, 2024 and 0.9260 CHF/€ as of December 31, 2023 for SGS, (ii) 1.1196 USD/€ as of September 30, 2024 and 1.1050 USD/€ as of December 31, 2023 for Concentrix
2 Including the market value of earn-out shares at September 30, 2024, i.e., €7m, and at December 31, 2023, i.e., €27m
3 GBL's ownership in Canyon, excluding shares held by GBL Capital (additional indirect ownership of 1.34% as of September 30, 2024 and as of December 31, 2023)
4 Valued at the acquisition cost of the management companies less any impairment in value
5 The Concentrix note was monetized in Q3 2024; GBL has a residual receivable of €4m as of September 30, 2024
Net debt decreased from €2.0bn as of December 31, 2023 to €1.3bn as of September 30, 2024. This decrease mainly reflects divestments and distributions of €1,342m and cash earnings of €315m, partially offset by investments of - €260m (including share buybacks) and the dividend paid by GBL for the year 2023 (- € 380m).
| €m | Gross cash | Gross debt | Net debt |
|---|---|---|---|
| Position as of December 31, 2023 | 1,556.01 | (3,577.9) | (2,021.9) |
| Cash earnings | 315.2 | - | 315.211 |
| Dividend FY 2023 | (380.5) | - | (380.5) 1 |
| Investments | (260.2) | - | (260.2)1 |
| GBL (share buybacks) | (190.4) | - | (190.4)1 |
| Sienna Investment Managers | (32.4) | - | (32.4)1 |
| GBL Capital | (23.7) | - | (23.7)1 |
| Other | (13.7) | - | (13.7)1 |
| Divestments/Distributions | 1,342.0 | - | 1,342.01 |
| adidas | 999.3 | - | 999.31 |
| GBL Capital | 342.7 | - | 342.71 |
| Institutional bonds | (500.0) | 500.0 | - 1 |
| Other | (258.2)2 | 7.5 | (250.7)2 |
| Position as of September 30, 2024 | 1,814.3 | (3,070.4) | (1,256.1) |
The LTV3 stood at 7.3%. This compares to 11.4% at the end of December 2023.

Loan To Value
3 Includes gross cash and Concentrix note

1 Includes the Concentrix note, which was monetized in Q3 2024; GBL has a residual receivable of €4m as of September 30, 2024
2 Includes mainly (i) timing differences in some fund distributions received by GBL Capital and upstreamed to GBL (- €149m), (ii) dividends received from GBL Capital presented both in cash earnings and distributions (- €71m) and (iii) the net impact to set up the new group's carried interest scheme (- €27m)
| €m | September 30, 2024 | December 31, 2023 |
|---|---|---|
| Institutional bonds | (2,000) | (2,500) |
| Exchangeable bonds into Pernod Ricard shares | (500) | (500) |
| Convertible bonds into GBL shares | (500) | (500) |
| Other | (70) | (78) |
| Gross debt | (3,070) | (3,578) |
| Gross cash (excluding treasury shares) | 1,810 | 1,080 |
| Concentrix note | 4 | 476 |
| (Net debt)/Net cash | (1,256) | (2,022) |
The weighted average maturity of the gross debt is 3.9 years at the end of September 2024 (4.0 years at the end of December 2023).
The gross debt does not include the external investment commitments of GBL Capital, which total €831m at the end of September 2024 (€752m at the end of December 2023).
The Concentrix note was estimated at its present value for an amount of €476m at the end of December 2023, and was monetized in Q3 20241 .
As of September 30, 2024, committed credit lines amount to €2,450m, fully undrawn, and mature in 2029.
The liquidity profile (gross cash and undrawn committed credit lines) amounts to €4,260m at the end of September 2024, compared to €3,530m at the end of December 2023.
Finally, as of September 30, 2024, the 11.4m treasury shares correspond to 8.2% of the shares representing the capital on this date and are valued at €795m.
1 GBL has a residual receivable of €4m as of September 30, 2024

| Investment category | % of portfolio |
Investment | Strategy |
|---|---|---|---|
| Listed assets 2012 START OF THE PORTFOLIO REBALANCING |
• Leading companies in their sector, with a clear and sustainable business model • Majority or minority shareholdings with influence, enabling a position as a reference shareholder and an engaged role in the governance • Equity investments between €250m and €2bn |
• NAV growth • Diversification within this investment category • Cash flow generation to ensure the GBL dividend |
|
| Private assets 2019 START OF ACTIVITY |
• Leading companies in their sector, with a clear and sustainable business model • Mainly majority shareholdings • Equity investments from €300m and €1bn |
• NAV growth • Consolidation opportunities • Attractive returns thanks to agile structures • Less replicable portfolio |
|
| Indirect private assets 2013 START OF ACTIVITY (FORMERLY SIENNA CAPITAL) |
• Fund commitments and co-investments alongside funds in which GBL is invested • Private equity funds typically, but also other strategies (e.g., private credit, structured equity, secondaries, value-add infrastructure) • Exposure to venture capital, growth equity and hedge funds • Commitments/investments of up to €50m, with flexibility to invest higher amounts in exceptional circumstances |
• NAV growth • Portfolio diversification • Downside protection • Meaningful contributor to GBL's cash earnings |
|
| Asset management 2021 START OF ACTIVITY |
• Platform for third-party asset management • Over €40bn under management at the end of September 2024 |
• Generation of recurring revenues • Regular fundraising across strategies • Synergy of expertises gathered in a single platform • Benefits from GBL's network |
Listed assets include stakes in SGS, Pernod Ricard, adidas, Imerys, Umicore and Concentrix, among others. As an engaged long-term investor, GBL seeks to invest in high-quality companies that are primarily investment grade and with a leading sector position. GBL contributes to value creation through its involvement in the key governance bodies of its portfolio companies. Listed assets represent 63% of GBL's portfolio at the end of September 2024.

2 Please refer to company-specific publications for more detail

1 In accordance with IFRS 9, capital gains (losses) do not impact GBL's consolidated net result
and reiterated its FY 2024 outlook: (i) mid- to high-single-digit organic sales growth, (ii) M&A relaunch, (iii) improvement in adjusted operating income margin on sales, and (iv) strong free cash flow generation
The NAV of the listed assets as of September 30, 2024 stood at €10.6bn, compared to €11.4bn as of December 31, 2023. The evolution is partly attributable to a reduction in the group's stake in adidas, representing €999m, as GBL crystallized value on its investment. The increase in fair value amounted to + €184m, with significant contributions from SGS and adidas, thanks to strong double-digit share price increases. These positive share price evolutions compensated softer performances of Umicore, Pernod Ricard and Concentrix.
| Listed assets – NAV evolution | ||
|---|---|---|
| €m | 9M 2024 | Q3 2024 |
| NAV, beginning of period | 11,360 | 10,033 |
| Acquisitions | 13 | - |
| Disposals | (999) | - |
| Change in fair value | 184 | 525 |
| NAV, end of period | 10,557 | 10,557 |
| Listed assets – contribution to NAV | ||||||
|---|---|---|---|---|---|---|
| 9M 2024 | Q3 2024 | |||||
| €m | NAV | Change in fair value |
Change in fair value |
|||
| SGS | 3,624 | 783 | 613 | |||
| Pernod Ricard | 2,337 | (415) | 153 | |||
| adidas | 2,178 | 652 | 136 | |||
| Imerys | 1,384 | 60 | (177) | |||
| Umicore | 457 | (519) | (93) | |||
| Concentrix (ordinary + earn-out shares) | 409 | (398) | (122) | |||
| Ontex | 147 | 22 | 14 | |||
| TotalEnergies | 16 | (1) | (1) | |||
| GEA | 5 | 1 | 1 | |||
| Total | 10,557 | 184 | 525 |
Private assets include controlling stakes in Affidea, Sanoptis and Canyon (consolidated assets) as well as minority stakes in Voodoo and Parques Reunidos (non-consolidated assets or assets accounted for using the equity method). Given the attractive long-term potential of private assets, GBL has increased over time its involvement in this asset category, which represents 19% of the portfolio as of the end of September 2024.

1 Affidea (+ €192m), Sanoptis (+ €54m), Canyon (- €60m), Voodoo (+ €10m) and Parques Reunidos (+ €0m)

At the end of September 2024, the NAV stood at €3.3bn, an increase of + €196m compared to year-end 2023. This increase reflects, in particular, the uplift in fair value of healthcare platforms Affidea and Sanoptis at + €192m and + €54m, respectively.
| Private assets – NAV evolution | ||
|---|---|---|
| €m | 9M 2024 | Q3 2024 |
| NAV, beginning of period | 3,067 | 3,191 |
| Acquisitions | 1 | - |
| Disposals | - | - |
| Change in fair value | 195 | 72 |
| Affidea | 192 | 89 |
| Sanoptis | 54 | 12 |
| Canyon | (60) | (32) |
| Voodoo | 10 | 3 |
| Parques Reunidos | 0 | 0 |
| NAV, end of period | 3,263 | 3,263 |
| consolidated assets | 2,671 | 2,671 |
| non-consolidated assets or assets accounted for using the equity method |
593 | 593 |
Over the 9M 2024, the healthcare platforms reported an increase in NAV, driven by robust business development both organically and from M&A. From an operational perspective, Canyon continues to outperform its peers. However, the challenging market environment in 2024 has slightly impacted the 2025 outlook, and therefore valuation.
| Consolidated private assets – valuation1 | ||||||||
|---|---|---|---|---|---|---|---|---|
| €m | Acquisition year |
MoIC | NAV 9/30/2024 |
NAV 6/30/2023 |
Variation (3 months) |
NAV 12/31/2023 |
Variation (9 months) |
Major Drivers |
| Affidea | 2022 | 1.4x | 1,386 | 1,298 | + 89 | 1,195 | + 192 | Continued strong growth, both organic and from M&A, including the MedEuropa acquisition (closed in May 2024); Solid cash flow generation |
| Sanoptis | 2022 | 1.3x | 883 | 871 | + 12 | 829 | + 54 | High growth, from organic initiatives and M&A, combined with significantly expanded platform capabilities (e.g., successful entry into 4 new geographies, substantial reinforcement of shared functions and investments into new technologies) |
| Canyon | 2021 | 1.1x | 402 | 434 | - 32 | 460 | - 60 | Continued challenging market environment (i.e., oversupply leading to high discounts on certain bike categories), impacting 2024 and resulting in a slight downward revision of the 2025 financial outlook |
1 The private assets are valued quarterly at their fair value, using a multi-criteria approach (e.g., DCF, multiples, trading comps), in line with IPEV Valuation Guidelines. Acquisitions are held at cost for 12 months, provided this is the best estimate of fair value

The pan-European provider of advanced diagnostics and outpatient services
Acquired in 2022

€1,386m NAV as of 9/30/2024 + €192m compared to 12/31/2023
dlhgjh
| Key metrics, Affidea | ||||
|---|---|---|---|---|
| Evolution since | 9M | 9M | GBL entry - | |
| GBL's entry | 20242 | 20232 | LTM ending June 30, 2022 |
|
| Sales3 , €m |
+ 284 | 757 | 632 | 698 |
| Growth, % | + 41% | + 20% | + 19% | - |
| Organic growth1 , % |
+ 30% | + 13% | + 16% | - |
| EBITDA growth4 , % |
+ 57% | + 27% | + 22% | - |
| Number of locations5 | + 65 | 380 | 334 | 315 |
| Number of examinations, millions | + 19% | 24.2 | 22.8 | 26.8 |
Source: Non-audited internal reporting
3 Reported sales
5 Pro forma for acquisitions
1 Like-for-like growth, excluding impact of acquisitions done in the latest period and Covid-19 testing
2 Growth metrics vs. same period of previous year (at constant currency within the year)
4 Pro forma for the full latest period of acquisitions done in that period, excluding Covid-19 testing and equipment lease
A European leader in ophthalmology services
Acquired in 2022

| Key metrics1 , Sanoptis |
||||||
|---|---|---|---|---|---|---|
| Evolution | 9M | 9M | GBL entry - | |||
| since GBL's entry |
20242 | 20232 | LTM ending June 30, 2022 |
|||
| Sales, €m | + 322 | 518 | 419 | 350 | ||
| Growth, % | 95% | 24% | 42%3 | - | ||
| Organic growth4 , % |
20% | 11% | 11%3 | - | ||
| EBITDA growth, % | 95% | 18% | 46%3 | - | ||
| Number of locations | + 168 | 447 | 386 | 279 | ||
| Number of doctors | + 320 | 835 | 686 | 515 | ||
| Number of treatments5 , 000s |
+ 1,415 | 2,404 | 2,200 | 1,876 |
Source: Non-audited internal reporting
5 Core surgical and conservative (e.g., diagnostic) treatments

1 All periods include annualization of closed clinic M&A and clinic M&A projects with signed SPAs at the end of the period except for organic growth
2 Growth metrics vs. same period of last year
3 Restated reflecting updated signing date of pipeline M&A
4 Organic growth uses the perimeter of the earliest period annualized for closed clinic M&A
World's largest Direct-to-Consumer manufacturer of premium bikes
Acquired in 2021

€402m NAV as of 9/30/2024 - €60m compared to 12/31/2023
dlhgjh
| Key metrics1 , Canyon |
||||||
|---|---|---|---|---|---|---|
| Evolution since | 9M | 9M | GBL entry - | |||
| GBL's entry | 20242 | 20232 | FY 2020 | |||
| Sales, €m | + 417 | 655 | 621 | 408 | ||
| Growth, % | + 102% | 6% | 23% | - | ||
| Organic growth, % | + 102% | 6% | 23% | - | ||
| EBITDA growth3 , % |
+ 3% | (19)%4 | (6)%5 | - | ||
| Number of employees | + 665 | 1,655 | 1,695 | 990 |
Source: Non-audited internal reporting
5 Impacted by: (i) higher discounts on certain categories and (ii) a strong comparable period which benefited from the sale of high-margin models

1 At yearly average FX rates; local GAAP, pre IFRS
2 Growth metrics vs. same period of the previous year
3 Adjusted EBITDA
4 EBITDA decline mainly impacted by the reversal of one-off EBITDA adjustments accounted for in 2023 (adjustments for one-off supply chain issues incurred in Q3 2023). Excluding these adjustments, growth would be + 5%
One of the world's leading mobile game publishers by downloads
Minority stake taken in 2021

NAV as of 9/30/2024 + €10m compared to 12/31/2023
| Key metrics, Voodoo | ||
|---|---|---|
| 9M | 9M | |
| 20241 | 20231 | |
| Sales, €m | 430 | 390 |
| Growth, % | 10% | 14%2 |
2 Adjusted for a one-off effect in 9M 2022, when Voodoo enjoyed a revenue inflow related to a deal with a leading ad mediation platform

1 Growth metric vs. same period of previous year

A leading operator of leisure parks with a global presence
Minority stake since 2017 (company taken private in 2019)

+m
| Key metrics, Parques Reunidos | |||||
|---|---|---|---|---|---|
| 9M | 9M | ||||
| 2024 1 |
2023 1 |
||||
| Sales, €m | 714 | 699 | |||
| Growth, % | 2% | 3% |
1 Growth metric vs. same period of previous year


GBL Capital, established in 2013, is the group's indirect private asset activity that invests in funds and co-investments. The NAV of this activity represents 17% of GBL's portfolio as of the end of September 2024.
GBL Capital's NAV stood at €2.8bn at the end of September 2024. Funds represented 50% of total assets, co-investments 35% and Sienna branded funds and co-investments 9%. GBL Capital's value creation amounted to + €83m over the period, but due to high distributions (€343m), NAV decreased.
Distributions mainly came from funds Apheon (€201m), Sagard (€64m), Kartesia (€47m) and BDT (€16m) while the most significant contributions to value creation came from growth at Apheon (+ €48m) and Sagard (+ €21m).
The most significant investments were capital calls for ICONIQ (€32m) and in Sienna Private Credit (€29m). Moreover, in July 2024, GBL Capital concluded a secondary transaction with a leading institutional investor involving the disposal of a portion of certain fund interests, mainly managed by Sagard, for total proceeds of €102m. This disposal generated a capital gain of €13m. This institutional investor has committed to invest €40m to Sienna Private Equity Fund I.
| GBL Capital – NAV evolution | ||||||
|---|---|---|---|---|---|---|
| €m | NAV 9/30/2024 |
Value creation |
Distributions | Investments | Other | NAV 12/31/2023 |
| Funds | 1,432 | 74 | (338) | 51 | - | 1,644 |
| Co-investments | 1,002 | 3 | (1) | (9) | - | 1,009 |
| Sienna branded funds and co-investments | 263 | 5 | (3) | (36) | - | 297 |
| Other (GBL Capital cash and working capital) | 149 | - | - | 19 | 130 | - |
| Total | 2,845 | 83 | (343) | 24 | 130 | 2,951 |
| GBL Capital, NAV | ||||||
|---|---|---|---|---|---|---|
| €m | 12/31/2023 | Investments | Distributions | Value Creation | Other | 9/30/2024 |
| Apheon | 401.9 | 4.2 | (201.4) | 47.8 | - | 252.5 |
| Sagard | 326.6 | (46.8) | (63.8) | 21.5 | - | 237.5 |
| Human Capital | 174.6 | 8.6 | - | (1.8) | - | 181.4 |
| Backed | 154.5 | 8.4 | (3.7) | (4.4) | - | 154.9 |
| BDT | 133.6 | 0.6 | (16.3) | 1.3 | - | 119.2 |
| Marcho Partners | 96.5 | - | (0.1) | 3.8 | - | 100.2 |
| Kartesia | 133.0 | - | (47.4) | 4.8 | - | 90.4 |
| C2 Capital | 75.0 | 1.7 | - | (3.0) | - | 73.7 |
| ICONIQ | 15.8 | 32.3 | - | (1.2) | - | 46.9 |
| Stripes | 29.8 | 3.1 | - | (2.8) | - | 30.1 |
| 468 Capital | 18.0 | 6.7 | - | (1.2) | - | 23.6 |
| CIEP II | 19.0 | 0.6 | - | 1.4 | - | 20.9 |
| Griffin | 16.5 | 1.6 | (0.3) | (0.1) | - | 17.7 |
| Mérieux | 18.1 | 0.5 | (1.3) | (1.0) | - | 16.3 |
| PrimeStone | 15.9 | - | (0.3) | 0.6 | - | 16.2 |
| Alto Capital V | 1.2 | 13.3 | - | (0.2) | - | 14.4 |
| Epiris | - | 5.6 | (0.1) | 7.5 | - | 13.0 |
| Innovius | 6.6 | 2.5 | - | 0.0 | - | 9.1 |
| SPC | 7.6 | 1.0 | - | 0.2 | - | 8.8 |
| Dover | - | 3.7 | (0.3) | 0.9 | - | 4.3 |
| Warburg | - | 3.0 | (3.0) | 1.4 | - | 1.5 |
| Bregal | - | - | - | (1.1) | - | (1.1) |
| Funds | 1,644.3 | 50.8 | (338.0) | 74.5 | - | 1,431.6 |
| Upfield | 424.6 | - | - | (0.0) | - | 424.6 |
| Cepsa | 95.4 | 0.3 | - | 7.4 | - | 103.2 |
| opseo | 65.9 | - | - | 3.3 | - | 69.1 |
| proALPHA | 59.5 | - | - | 6.3 | - | 65.8 |
| svt Ceva |
52.5 40.4 |
- - |
- - |
3.2 3.5 |
- - |
55.7 43.9 |
| Commure | 39.8 | - | - | (0.5) | - | 39.3 |
| Wella | 32.2 | - | - | 2.2 | - | 34.4 |
| Elsan | 37.5 | - | - | (5.0) | - | 32.4 |
| Ginger | 30.8 | (4.9) | (1.0) | 2.3 | - | 27.2 |
| ADIT | 28.1 | (4.9) | (0.4) | 4.2 | - | 27.0 |
| Illumio | 24.3 | - | - | (0.3) | - | 24.0 |
| Transcarent | 17.7 | - | - | (0.2) | - | 17.4 |
| Canyon | 13.0 | - | - | (1.6) | - | 11.4 |
| Globality | 10.0 | - | - | - | - | 10.0 |
| Telenco | 9.4 | - | - | (0.5) | - | 8.9 |
| Sagard NewGen Pharma | 5.0 | - | - | (0.0) | - | 5.0 |
| Klarna | 2.6 | - | - | - | - | 2.6 |
| Cosmetics company | 20.8 | - | - | (20.8) | - | - |
| Co-investments | 1,009.4 | (9.5) | (1.4) | 3.4 | - | 1,002.0 |
| Sienna Private Equity | 150.4 | (41.7) | (1.8) | 4.2 | - | 111.2 |
| Sienna Private Credit | 74.3 | 29.2 | (1.5) | 2.9 | - | 104.9 |
| Sienna Venture Capital | 32.1 | 6.2 | - | (2.2) | - | 36.1 |
| Sienna Private Assets | ||||||
| Allocation | - | 10.0 | - | 0.5 | - | 10.5 |
| Sienna Opportunities funds | 40.2 | (40.1) | - | (0.1) | - | - |
| Sienna branded funds and | 297.1 | (36.4) | (3.3) | 5.3 | - | 262.6 |
| co-investments | ||||||
| Other (GBL Capital cash and | - | 18.8 | - | - | 130.3 | 149.0 |
| working capital) | ||||||
| Total GBL Capital | 2,950.8 | 23.7 | (342.7) | 83.1 | 130.3 | 2,845.2 |


Sienna Investment Managers ("Sienna IM") is a multi-expertise pan-European asset manager, building innovative investment strategies spanning listed and private assets, with a long-term perspective and a strong ESG focus. Sienna IM's third-party assets under management total over €40bn as of the end of September 2024.
| Sienna Investment Managers – Net economic result | ||||
|---|---|---|---|---|
| 9/30/2024 | ||||
| €m | Net economic result | |||
| Revenues | 892 | |||
| Operating expenses | (88) | |||
| EBITDA | 1 | |||
| Financial results | (1) | |||
| Other | (26) | |||
| Net economic result | (25) |
2 Includes €9m of fees from GBL Capital

1 Fonds communs de placement à risque = high-yield mutual funds
| €m | End of September | End of December | ||
|---|---|---|---|---|
| (Group's share) | 2024 | 2023 | 2023 | Variation2 |
| Consolidated net result | 55 | 1,726 | 1,723 | (1,671) |
| Consolidated net result per share3 | 0.41 | 12.22 | 12.28 | (11.80) |
| Cash earnings | 315 | 371 | 414 | -15.0% |
| Cash earnings per share3 | 2.28 | 2.53 | 2.82 | -9.9% |
| Net asset value | 16,330 | 16,018 | 16,671 | -2.0% |
| Net asset value per share3 | 117.99 | 109.19 | 113.64 | +3.8% |
| Market capitalization | 9,681 | 10,351 | 10,448 | -7.3% |
| Market capitalization per share3 | 69.95 | 70.56 | 71.22 | -1.8% |
| Discount | 40.7% | 35.4% | 37.3% | +3.4% |
| Net investments / (divestments) |
(1,082) | (506) | (595) | (576) |
| Net cash / (Net debt) | (1,256) | (2,164) | (2,022) | 766 |
| Loan To Value | 7.3% | 12.4% | 11.4% | -4.0% |
3 Calculation per share based on the number of shares issued as of September 30, 2024, December 31, 2023 and September 30, 2023 (138.4m, 146.7m and 146.7m respectively), except for the net result per share which refers, in accordance with IFRS, to the weighted average number of shares (133.2m, 140.3m and 141.3m respectively) used to determine the basic earnings per share

1 The definitions of alternative performance indicators and, where applicable, their calculation methods can be found in the glossary available on GBL's website: www.gbl.com/en/glossary
2 Variation between September 2024 and September 2023 for the consolidated net result, cash earnings and net investments/(divestments), and between September 2024 and December 2023 for net asset value, market capitalization, discount, net debt and Loan To Value
| €m | September 30, 2024 | September 30, | ||||||
|---|---|---|---|---|---|---|---|---|
| Group's share | 2023 | |||||||
| Cash earnings |
Mark to market and other non-cash items |
Operating companies (associated or consolidated) |
GBL Capital |
Sienna Investment Managers |
Eliminations, capital gains, impairments and reversals |
Consolidated | Consolidated | |
| Profit (loss) of associates and consolidated operating companies |
- | - | (141.5) | 31.4 | (12.1) | - | (122.2) | 65.0 |
| Net dividends from investments |
345.8 | 2.3 | - | - | - | (134.1) | 214.1 | 238.2 |
| Interest income (expenses) | (1.5) | (3.9) | - | (5.6) | (0.4) | - | (11.5) | (31.3) |
| Other financial income (expenses) |
10.0 | (1.2) | - | 70.1 | - | (25.5) | 53.5 | 354.2 |
| Other operating income (expenses) |
(40.6) | (25.8) | - | (41.3) | (12.5) | - | (120.2) | (193.7) |
| Gains (losses) from disposals, impairments and reversal of non-current assets |
1.6 | - | - | 40.5 | (0.4) | 0.1 | 42.0 | 1,294.4 |
| Taxes | (0.2) | - | - | (0.4) | - | - | (0.5) | (0.3) |
| IFRS consolidated net result 2024 (Group's share) (9 months) |
315.2 | (28.6) | (141.5) | 94.8 | (25.4) | (159.4) | 55.1 | |
| IFRS consolidated net result 2023 (Group's share) (9 months) |
371.0 | 103.1 | 1,337.1 | 131.0 | (14.6) | (201.1) | 1,726.5 |
| €m | September 30, 2024 | September 30, 2023 |
|---|---|---|
| Net dividends from investments | 345.8 | 416.9 |
| Interest income (expenses) | (1.5) | (29.0) |
| GBL Capital interests | 9.5 | 1.1 |
| Other interest income (expenses) | (11.0) | (30.1) |
| Other financial income (expenses) | 10.0 | 20.5 |
| Other operating income (expenses) | (40.6) | (37.4) |
| Gains (losses) from disposals, impairments and reversal of non-current assets |
1.6 | - |
| Taxes | (0.2) | (0.1) |
| Total | 315.2 | 371.0 |
Net dividends from investments received as of September 30, 2024 (€346m) decreased in comparison with September 30, 2023, mainly following the exceptional dividend paid by Imerys in 2023 in addition to its ordinary dividend and linked to the disposal of the HTS business line (impact of - €109m) and the absence of contribution from Holcim as a consequence of the exit from the residual position during 2023 (impact of - € 34m), partially compensated by a contribution from GBL Capital in 2024 (impact of €71m).
1 The definitions of alternative performance indicators and, where applicable, their calculation methods can be found in the glossary available on GBL's website: www.gbl.com/en/glossary
| €m | September 30, 2024 | September 30, 2023 |
|---|---|---|
| SGS | 125.6 | 117,7 |
| GBL Capital | 71.5 | - |
| Imerys | 62.6 | 178.6 |
| Pernod Ricard | 40.5 | 35.4 |
| Umicore | 31.4 | 31.4 |
| Concentrix | 7.0 | - |
| adidas | 6.3 | 8.2 |
| TotalEnergies | 0.7 | 0.6 |
| GEA | 0.1 | 9.9 |
| Holcim | - | 33.6 |
| Mowi | - | 1.4 |
| Other | 0.1 | 0.1 |
| Total | 345.8 | 416.9 |
Interest income (expenses) (- €1m) mainly comprise (i) income from gross cash (€22m compared to €12m as of September 30, 2023), (ii) interest from the Concentrix note (€16m compared to €0m as of September 30, 2023), (iii) interest income from GBL Capital (€10m compared to €1m as of September 30, 2023) partially balanced by (iv) interest expenses related to the institutional bonds and the Pernod Ricard exchangeable bond (- €46m compared to - €41m as of September 30,2023).
Other financial income (expenses) (€10m) mainly comprise (i) the dividend received on treasury shares for €25m (€22m as of September 30, 2023) and (ii) yield enhancement income of €4m (€5m as of September 30, 2023), partially balanced by (iii) fees on financial transactions (- €13m).
Gains (losses) from disposals, impairments and reversal of non-current assets (€2m) is composed of the accounting result1 on the partial disposal of the Concentrix note.
| €m | September 30, 2024 | September 30, 2023 |
|---|---|---|
| Net dividends from investments | 2.3 | (0.1) |
| Interest income (expenses) | (3.9) | (4.9) |
| Other financial income (expenses) | (1.2) | 103.3 |
| Other operating income (expenses) | (25.8) | 4.8 |
| Total | (28.6) | 103.1 |
Other operating income (expenses) notably include the impact of the new group's carried interest scheme implemented in January 2024 (- €27m).
1 Excluding bank fees

In accordance with accounting principles, GBL includes in its accounts its share of the net results of the participations in which it holds the majority of the capital or on which it has a significant influence.
| €m | September 30, 2024 | September 30, 2023 |
|---|---|---|
| Profit (loss) of associates and consolidated operating companies |
(141.5) | 51.1 |
| Other financial income (expenses) | - | 106.5 |
| Other operating income (expenses) | - | (112.3) |
| Gains (losses) on disposals, impairments and reversals of non-current assets |
- | 1,291.8 |
| Total | (141.5) | 1,337.1 |
Profit (loss) of associates and consolidated operating companies amounts to - €142m compared to €51m as of September 30, 2023.
| €m | September 30, 2024 | September 30, 2023 |
|---|---|---|
| Imerys | (78.8) | 100.9 |
| Sanoptis | (39.2) | (31.5) |
| Affidea | (16.3) | (33.2) |
| Parques Reunidos/Piolin II | (7.0) | 0.6 |
| Canyon | (0.2) | (0.2) |
| Webhelp | - | 14.4 |
| Total | (141.5) | 51.1 |
Net current income from continued activities, group's share, increases 11.4% to €214m as of September 30, 2024 (€192m as of September 30, 2023). The adjusted EBITDA amounts to €532m (€517m as of September 30, 2023). The net result, group's share, amounts to - €143m as of September 30, 2024 (€184m as of September 30, 2023).
The net result, group's share as of September 30, 2024 is impacted by the recycling in the income statement of translation adjustments relating to assets serving the paper market (mainly arising from the devaluation of the Brazilian real) following their disposal. Imerys shareholders' equity and cash position are not affected by this €302m loss.
Imerys contributes - €79m to GBL's result as of September 30, 2024 (€101m as of September 30, 2023), reflecting the variation in net income, group's share, and the 54.98% consolidation rate for Imerys (54.91% as of September 30, 2023).
The press release relating to Imerys' results as of September 30, 2024 is available at www.imerys.com.
As of September 30, 2024, Sanoptis' contribution to GBL's result amounts to - €39m (- €31m as of September 30, 2023), based on a net result of - €48m (- €40m as of September 30, 2023) and taking into account an integration rate of 83.11% (83.16% as of September 30, 2023).
As of September 30, 2024, Affidea's contribution to GBL's result amounts to - €16m (- €33m as of September 30, 2023), based on a net result of - €17m (- €40m as of September 30, 2023) and taking into account an integration rate of 98.98% (99.00% as of September 30, 2023).

As of September 30, 2024, the contribution amounts to - €7m (€1m as of September 30, 2023), considering a net result of Piolin II of - €30m (€3m as of September 30, 2023) and taking into account an integration rate of 23.10% (23.10% as of September 30, 2023).
As of September 30, 2024, Canyon's contribution to GBL's result amounts to - €0m (- €0m as of September 30, 2023), based on a net result of €0m (- €2m as of September 30, 2023) and taking into account an integration rate of 48.78% (47.96% as of September 30, 2023).
As of September 30, 2023, Webhelp's contribution to GBL's result amounted to €14m.
In addition, the other financial income (expenses) and other operating income (expenses) reflected the change in debts to Webhelp's minority shareholders.
At the closing of the sale of Webhelp as of September 25, 2023, the debt on minority shareholders was extinguished, without any impact on GBL's cash.
| €m | September 30, 2024 | September 30, 2023 |
|---|---|---|
| Profit (loss) of associates and consolidated operating companies |
31.4 | 20.6 |
| Interest income (expenses) | (5.6) | 2.5 |
| Other financial income (expenses) | 70.1 | 146.3 |
| IFRS 9 | 66.5 | 125.9 |
| Other | 3.7 | 20.5 |
| Other operating income (expenses) | (41.3) | (40.9) |
| Gains (losses) on disposals, impairments and reversals of non-current assets |
40.5 | 2.5 |
| Taxes | (0.4) | (0.1) |
| Total | 94.8 | 131.0 |
The contribution to GBL's results as of September 30, 2024 of GBL Capital's investments consolidated or accounted for by the equity method amounts to €31m, compared to €21m a year earlier:
| €m | September 30, 2024 | September 30, 2023 |
|---|---|---|
| AMB IV | 35.7 | 34.2 |
| Operating subsidiaries of AMB III | 0.6 | (6.4) |
| Landlife Holding | - | (0.0) |
| AMB I & II | (0.0) | (0.0) |
| Canyon | (0.0) | (0.0) |
| Mérieux Participations 2 | (0.5) | (10.0) |
| Backed 1, Backed 2 and Backed Encore 1 | (4.4) | 2.8 |
| Total | 31.4 | 20.6 |
Interest income (expenses) (- €6m) include notably interest charges to GBL (- €10m compared to - €1m as of September 30, 2023).

Other financial income (expenses) mainly reflect the change in fair value of the investments not consolidated or not accounted for by the equity method, in application of IFRS 9, for a total amount of €66m (€126m as of September 30, 2023), out of which mainly Sagard funds I - 4 (€25m), Epiris (€10m), Cepsa (€8m) and a cosmetics company (- €21m). As of September 30, 2023, this section included mainly Upfield (€25m), Sagard funds I - 4 (€20m), Marcho Partners (€16m), Kartesia funds (€15m), BDT (€11m) and Cepsa (- €11m).
The gains (losses) on disposals, impairments and reversals of non-current assets mainly include, as of September 30, 2024, the net capital gain following the sale of Beltaste-Vanreusel and Visionnaire by AMB III (€41m).
| € m | September 30, 2024 | September 30, 2023 |
|---|---|---|
| Profit (loss) of associates and consolidated operating companies |
(12.1) | (6.6) |
| Interest income (expenses) | (0.4) | - |
| Other operating income (expenses) | (12.5) | (8.0) |
| Gains (losses) on disposals, impairments and reversals of non-current assets |
(0.4) | (0.0) |
| Total | (25.4) | (14.6) |
The contribution to GBL's results as of September 30, 2024 of Sienna Investment Managers' investments consolidated or accounted for by the equity method amounts to - €12m, compared to - €7m a year earlier:
| €m | September 30, 2024 | September 30, 2023 |
|---|---|---|
| Sienna Gestion | (11.1) | (0.3) |
| Sienna Real Estate | (1.2) | (5.4) |
| Sienna Private Credit | 0.1 | (0.9) |
| Total | (12.1) | (6.6) |
| €m | September 30, 2024 | September 30, 2023 |
|---|---|---|
| Net dividends from investments | (134.1) | (178.6) |
| Other financial income (expenses) | (25.5) | (22.5) |
| Gains (losses) from disposals, impairments and reversal of non-current assets |
0.1 | - |
| Total | (159.4) | (201.1) |
Net dividends from investments (associates or consolidated companies) are eliminated and are related in 2024 to GBL Capital (- €71m) and Imerys (- €63m compared to - €179m as of September 30, 2023).
The other financial income (expenses) include mainly the elimination of the dividend on treasury shares amounting to - €25m (- €22m as of September 30, 2023).
The following table presents GBL's IFRS income statement broken down into six segments:
The results of a segment include all the items directly attributable to it.
| Capital/SIM Sanoptis Holding Canyon Affidea Consolidated Consolidated Imerys GBL Share of profit (loss) of associates (7.0) - - - - 30.8 23.8 27.6 Net dividends from investments 214.1 - - - - - 214.1 238.2 Other operating income (expenses) from (66.4) - (0.4) (0.2) (0.2) (64.8) (132.0) (83.7) investing activities Gains (losses) from disposals, impairments and reversals of non 1.8 - - - - 45.0 46.7 3.1 current assets from investing activities Financial income (expenses) from (22.1) - - (0.0) - 73.6 51.6 215.0 investing activities Profit (loss) before taxes from investing 120.4 - (0.4) (0.2) (0.2) 84.6 204.1 400.2 activities - continuing operations Turnover - 2,773.2 653.7 749.3 488.3 77.7 4,742.2 4,651.0 - Raw materials and consumables - (909.7) (414.9) (84.1) (93.8) (0.0) (1,502.5) (1,588.1) - Employee expenses - (675.1) (79.6) (383.9) (201.2) (32.0) (1,371.8) (1,251.9) - Depreciation on tangible and intangible - (211.6) (33.7) (99.9) (44.0) (6.3) (395.4) (384.1) - assets Other operating income (expenses) from - (672.6) (110.1) (130.2) (85.6) (36.1) (1,034.6) (1,027.5) - operating activities Gains (losses) from disposals, impairments and reversals of non - (334.7) - 0.6 - 0.9 (333.1) (61.9) - current assets from operating activities Financial income (expenses) from - (39.2) (13.1) (56.6) (99.7) (5.5) (214.0) (195.0) - operating activities Profit (loss) before taxes from consolidated operating activities - - (69.6) 2.3 (4.8) (35.9) (1.2) (109.3) 142.6 continuing operations - Income taxes (0.2) (71.1) (2.0) (11.1) (11.2) (0.9) (96.5) (85.5) - Profit (loss) from continuing operations 120.2 (140.7) (0.1) (16.2) (47.3) 82.4 (1.7) 457.3 - Profit (loss) from consolidated operating activities - discontinued - - - - - - - 1,355.8 - operations Consolidated profit (loss) for the period 120.2 (140.7) (0.1) (16.2) (47.3) 82.4 (1.7) 1,813.0 - Attributable to the group 120.2 (78.8) (0.2) (16.3) (39.2) 69.4 55.1 1,726.5 - Attributable to non-controlling interests - (61.9) 0.1 0.1 (8.1) 13.0 (56.8) 86.6 - September 30, September 30, Profit (loss) per share (€) 2024 2023 Basic - continuing operations 0.41 2.84 |
€m | September 30, 2023 |
||||
|---|---|---|---|---|---|---|
| Strategic Update | November 7, 2024 |
|---|---|
| Annual results 2024 | March 13, 2025 |
| Results as of March 31, 2025 | May 2, 2025 |
| Ordinary General Meeting 2025 | May 2, 2025 |
| Dividend payment | May 13, 2025 |
| Report on payments to governments available on GBL's website | May 30, 2025 |
| Half-year results 2025 | July 31, 2025 |
These dates may be subject to change.
February 11 – March 13, 2025 April 17 – May 2, 2025 July 1 – July 31, 2025
Xavier Likin Chief Financial Officer Tel: + 32 2 289 17 72 [email protected]
Alison Donohoe Head of Investor Relations Tel : +32 2 289 17 64 [email protected]
Groupe Bruxelles Lambert ("GBL") is an established investment holding company, with seventy years of stock exchange listing and a net asset value of €16.3bn at the end of September 2024. As a leading and active investor in Europe, GBL focuses on long-term value creation with the support of a stable family shareholder base. As a responsible company and investor, GBL perceives ESG factors as being inextricably linked to value creation.
GBL aims to grow its diversified high-quality portfolio of listed, private and alternative investments.
GBL is focused on delivering meaningful growth by providing attractive returns to its shareholders through a combination of growth in its net asset value per share, a sustainable dividend and share buybacks.
GBL is listed on Euronext Brussels (Ticker: GBLB BB; ISIN code: BE0003797140) and is included in the BEL20 index.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.